This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


2h8h

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2h8h.gif|left|200px]]
+
{{Seed}}
 +
[[Image:2h8h.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2h8h| PDB=2h8h | SCENE= }}
{{STRUCTURE_2h8h| PDB=2h8h | SCENE= }}
-
'''Src kinase in complex with a quinazoline inhibitor'''
+
===Src kinase in complex with a quinazoline inhibitor===
-
==Overview==
+
<!--
-
Src family kinases (SFKs) are nonreceptor tyrosine kinases that are reported to be critical for cancer progression. We report here a novel subseries of C-5-substituted anilinoquinazolines that display high affinity and specificity for the tyrosine kinase domain of the c-Src and Abl enzymes. These compounds exhibit high selectivity for SFKs over a panel of recombinant protein kinases, excellent pharmacokinetics, and in vivo activity following oral dosing. N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-( tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine (AZD0530) inhibits c-Src and Abl enzymes at low nanomolar concentrations and is highly selective over a range of kinases. AZD0530 displays excellent pharmacokinetic parameters in animal preclinically and in man (t(1/2) = 40 h). AZD0530 is a potent inhibitor of tumor growth in a c-Src-transfected 3T3-fibroblast xenograft model in vivo and led to a significant increase in survival in a highly aggressive, orthotopic model of human pancreatic cancer when dosed orally once daily. AZD0530 is currently undergoing clinical evaluation in man.
+
The line below this paragraph, {{ABSTRACT_PUBMED_17064066}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 17064066 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_17064066}}
==About this Structure==
==About this Structure==
Line 29: Line 33:
[[Category: Rowsell, S.]]
[[Category: Rowsell, S.]]
[[Category: Src kinase]]
[[Category: Src kinase]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 05:59:30 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 17:15:19 2008''

Revision as of 14:15, 28 July 2008

Image:2h8h.png

Template:STRUCTURE 2h8h

Src kinase in complex with a quinazoline inhibitor

Template:ABSTRACT PUBMED 17064066

About this Structure

2H8H is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor., Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Norman RA, Olivier A, Otterbein L, Ple PA, Warin N, Costello G, J Med Chem. 2006 Nov 2;49(22):6465-88. PMID:17064066

Page seeded by OCA on Mon Jul 28 17:15:19 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2h8h"
Personal tools